for ciprofloxacin/ceftazidime treatments , respectively , the evaluated infections were : pyelonephritis ( 16 patients/nine patients ) , pneumonia ( three/five ) , soft-tissue infections ( four/zero ) , spontaneous peritonitis ( five/two ) , primary bacteremia ( three/eight ) , and other ( two/two ) .
C0008809
ciprofloxacin
C0034186
pyelonephritis